ABOLmed was founded in April 1998. Six months later the Company already started the production of cephalosphorin antibiotics at its newly established pharmaceutical plant in Vidnoye (Moscow Region).
In December 2004 ABOLmed launched the first manufacturing line of its new pharmaceutical plant in Novosibirsk the construction of which took four years. This plant was built in full accordance with international GMP standards set for enterprises in pharmaceutical industry.
Along with product quality the Company places special emphasis on all the production factors without any exception, i.e. air conditions, water, work clothing, primary package materials, etc. est..
The plant is equipped with production lines supplied by the Italian firm IMA, one of the world's leading manufacturers of equipment for pharmaceutical enterprises. The professionals working in the plant have appropriate education, high-level skills and long-term experience in the pharmaceutical industry.
The continuous implementation of advanced technologies, maintenance of strong development rates, guaranteed quality and efficiency of manufactured products, realization of several research programs aimed at the development of proprietary drugs – all this allows the Company to retain present positions as the leading Russian manufacturer of four generations of cephalosporin antibiotics that are therapeutically equivalent to proprietary drugs of renowned western firms. This fact was repeatedly confirmed by multiple clinical studies on the base of the A.V.Vishnevsky Institute of Surgery (Moscow), Institute of Pediatry (Moscow), N.N.Burdenko Head Military Hospital (Moscow), N.V.Sklifosovsky Emergency Care Institute (Moscow), Research Center of Obstetrics, Gynecology and Perinatology (Moscow), Research Institute of General Critical Care Medicine (Moscow), Research Institute of Clinical Immunology (Novosibirsk), Altai State Medical University (Barnaul), Research Institute of Maternity and Childhood protection (Khabarovsk) and many other respected Russian clinics.
ABOLmed produces a range of antibiotics for parenteral use that are well-known among clinicians under such trade names as Nacef® (cefazoline), Anaerocef® (cefoxitin), Cefamabol® (cefamandol), Cefurabol® (cefuroxime), Cefabol® (cefotaxime), Ceftriabol® (ceftriaxone), Cefoperabol® (cefoperazone), Vicef® (ceftazidiume), Sulperacef® (cefoperazone/sulbactam), Maxycef® (cefepime), Urofosfabol® (fosfomycine) and Meropenabol® (meropenem).
With a team of high-skilled researchers including a number of MDs, ABOLmed conducts scientific investigations in cooperation with five institutes of the Russian Academy of Sciences and the Russian Academy of Medical Sciences. The innovative development activity of the Company allowed it to obtain 15 patents for original drug substances designed for creation of next-generation antimicrobial, anti-inflammatory and antitumor pharmaceuticals.
The firm pays great attention to the training of practicing physicians in the field of rational chemotherapy of infectious and inflammatory diseases. ABOLmed organizes and conducts educational seminars, publishes special scientific information handbooks, supports the all-Russia scientific magazine "Issues of Clinical Medicine", regularly acts as a sponsor for Russian and international medical forums.
ABOLmed is committed to creating and developing a world-class Russian pharmacological company with the purpose to address in full the needs of healthcare organizations in Russia in advanced medicines that are able to replace imported drugs, as well as to enter the international pharmacological market with proprietary solutions.
Never stop, always be leader, which means every time and in everything be ahead – this remains the philosophy of ABOLmed since the Company's inception.
